Belma Zachariah
Family · Lewisville, TXNPI 1568074532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,693 and has fallen 55.7% since, to $749 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$836
- Novo Nordisk$623
- AstraZeneca$529
- Boehringer Ingelheim$306
- Sanofi-aventis U.S. LLC$298
- Dexcom, Inc.$278
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,672100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $836 |
| Novo Nordisk | 34 | $623 |
| AstraZeneca | 28 | $529 |
| Boehringer Ingelheim | 17 | $306 |
| Sanofi-aventis U.S. LLC | 14 | $298 |
| Dexcom, Inc. | 15 | $278 |
| Bayer | 15 | $230 |
| Johnson & Johnson | 12 | $216 |
| Amgen | 13 | $193 |
| Pfizer | 8 | $192 |
| Exact Sciences | 11 | $189 |
| Mannkind Corporation | 10 | $188 |
| GSK | 10 | $171 |
| Zealand Pharma US, Inc. | 9 | $157 |
| Merck | 9 | $155 |
| Seqirus USA Inc | 8 | $153 |
| Insulet Corporation | 4 | $122 |
| Xeris Pharmaceuticals, Inc. | 6 | $120 |
| Amneal Pharmaceuticals LLC | 7 | $104 |
| Amarin Pharma, Inc. | 5 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $84 |
| AbbVie | 4 | $82 |
| Novartis | 2 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $46 |
| Dynavax Technologies Corporation | 3 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Cequr Corporation | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Ascensia Diabetes Care US Inc. | 1 | $13 |
How this compares
$5,684 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $16,961 |
| OzempicSemaglutide | 11 | $16,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,687 |
| PaxlovidNirmatrelvir/Ritonavir | 18 | $1,429 |
| Levothyroxine Sodium | 67 | $954 |
| Rosuvastatin Calcium | 50 | $798 |
| Atorvastatin Calcium | 80 | $768 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $675 |
| Montelukast Sodium | 61 | $641 |
| Pantoprazole Sodium | 36 | $537 |
| Losartan Potassium | 56 | $498 |
| Gabapentin | 22 | $477 |
| Celecoxib | 15 | $427 |
| Omeprazole | 21 | $426 |
| Fluticasone Propionate | 35 | $411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $306 | $16,96111 claims |
| Novo NordiskOzempic | $623 | $16,61811 claims |
| GSKTrelegy Ellipta | $171 | $6,68711 claims |
| PfizerPaxlovid | $192 | $1,42918 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $104 | $95467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Lewisville
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.